China SXT Pharmaceuticals, Inc.
SXTC · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D46Loss-making Chinese TCM nano-cap with shrinking revenue and VIE/China-governance overhang.
Strengths
- Clean balance sheet — debt/equity 0.006 and current ratio 3.5 (49th pct)
- Adequate cash ($18.1M, 33.6th pct) relative to a modest ~$2.3M annual loss
Risks
- Negative returns (ROA -15%, ROE -21%) and revenue down 10% YoY despite flattering sector percentiles
- VIE structure, PRC regulatory/CSRC and HFCAA risk, plus customer concentration and limited operating history
Key metrics
Return on equity
-21.4%
Return on assets
-15.2%
ROIC
-13.6%
Debt / equity
0.0×
Current ratio
3.5×
EBITDA
-$3M
Tangible book value
$15M
Cash & investments
$18M
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2025-07-31 | 2025-03-31 | 0001213900-25-069688 ↗ |
| 20-F | 2024-08-13 | 2024-03-31 | 0001213900-24-068266 ↗ |
| 20-F | 2023-07-31 | 2023-03-31 | 0001213900-23-061294 ↗ |
| 20-F | 2022-07-18 | 2022-03-31 | 0001213900-22-039838 ↗ |
| 20-F | 2021-08-13 | 2021-03-31 | 0001213900-21-042555 ↗ |
| 20-F | 2020-07-31 | 2020-03-31 | 0001213900-20-019503 ↗ |
| 20-F | 2019-08-15 | 2019-03-31 | 0001213900-19-016026 ↗ |